The period in brief – financial summary for the first quarter 2025 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 11,1 million (SEK 11,4 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...
Read MoreThe period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...
Read MoreDue to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...
Read MoreFirst quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...
Read MoreFirst quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the...
Read MoreFirst quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million)....
Read MorePERIOD 1 JAN – 31 MARCH 2018 IN BRIEF • Net sales amounted to SEK 0 million (0 million) • R & D expenses amounted to SEK 11.8 million (8.3 M) • Operating profit amounted to SEK -12.5 million (-9.7 million) •...
Read MoreThe period January to March 2016 in brief R&D expenses for the period amounted to SEK 4.2m (SEK 4.2m). Operating income for the period amounted to SEK -5.1m (SEK 4.9m). Income after financial items for the period amounted to...
Read MoreIn 2013 Kancera changed from the RFR2 regulations, applicable to companies in groups, to BFN ́s complementary regulation K3. The full year report and consolidated accounts fulfill the requirements of Nasdaq First North for the accounting of Kancera AB....
Read More